RO6870810联合维奈克拉和利妥昔单抗治疗复发难治性弥漫大B细胞淋巴瘤的1b期研究
该1b期剂量递增研究评估了BET抑制剂RO6870810联合BCL-2抑制剂维奈克拉及利妥昔单抗在复发/难治性DLBCL患者中的安全性、耐受性和初步疗效。总缓解率为38.5%,完全缓解率20.5%,48%的缓解持续时间≥180天。
要点
- 双药最大耐受剂量为RO 0.65 mg/kg联合维奈克拉600 mg;三药为RO 0.45 mg/kg、维奈克拉600 mg、利妥昔单抗375 mg/m2。
- 总缓解率38.5%,完全缓解率20.5%,48%的缓解持续≥180天。
- 常见3-4级不良事件为中性粒细胞减少(28%)、贫血和血小板减少(各23%)。
核心结论
- RO6870810联合维奈克拉和利妥昔单抗在复发/难治性DLBCL中显示出初步疗效和可管理的毒性。
研究设计与样本
- 1b期剂量递增研究,采用3+3设计确定RO联合维奈克拉双药安全性,后续队列加入利妥昔单抗。
主要发现
- 双药剂量限制性毒性包括3级发热性中性粒细胞减少、4级腹泻和低镁血症;三药增加3级高胆红素血症和4级腹泻。
- 双药最大耐受剂量为RO 0.65 mg/kg联合维奈克拉600 mg;三药最大耐受剂量为RO 0.45 mg/kg、维奈克拉600 mg、利妥昔单抗375 mg/m2。
- 最常见3-4级不良事件为中性粒细胞减少(28%)、贫血和血小板减少(各23%)。
- 总缓解率(改良Lugano标准)为38.5%,完全缓解8例(20.5%),48%的缓解持续≥180天。
- 单核细胞CD11b持续下降提示RO具有药效动力学活性。
关键数值与推荐
- 双药最大耐受剂量:RO 0.65 mg/kg联合维奈克拉600 mg。
- 三药最大耐受剂量:RO 0.45 mg/kg、维奈克拉600 mg、利妥昔单抗375 mg/m2。
- 总缓解率38.5%,完全缓解率20.5%。
临床怎么用
- 该联合方案在复发/难治性DLBCL中显示初步活性,但需优化给药方案并明确疗效预测因素后方可推广临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bromodomain and extraterminal (BET) proteins are transcriptional activators for multiple oncogenic processes in diffuse large B-cell lymphoma (DLBCL), including MYC, BCL2, E2F, and toll-like receptor signaling. We report results of a phase 1b dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 (RO) combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory DLBCL. RO was delivered for 14 days of a 21-day cycle, whereas venetoclax was delivered continuously. A 3 + 3 escalation design was used to determine the safety of the RO+venetoclax doublet; rituximab was added in later cohorts. Thirty-nine patients were treated with a median of 2.8 cycles (range, 1-11). Dose-limiting toxicities included grade 3 febrile neutropenia, grade 4 diarrhea, and hypomagnesemia for the doublet; and grade 3 hyperbilirubinemia and grade 4 diarrhea when rituximab was added. The doublet maximum tolerated dose (MTD) was determined to be 0.65 mg/kg RO+600 mg venetoclax; for RO+venetoclax+rituximab, the MTDs were 0.45 mg/kg, 600 mg, and 375 mg/m2, respectively. The most frequent grade 3 and 4 adverse events were neutropenia (28%) and anemia and thrombocytopenia (23% each). Responses were seen in all cohorts and molecular subtypes. Sustained decreases in CD11b on monocytes indicated pharmacodynamic activity of RO. Overall response rate according to modified Lugano criteria was 38.5%; 48% of responses lasted for ≥180 days. Complete response was observed in 8 patients (20.5%). Optimization of the treatment schedule and a better understanding of predictors of response would be needed to support broader clinical use. This trial is registered on www.clinicaltrials.gov as NCT03255096.
引用
- Dickinson M, Briones J, Herrera AF, et al. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Adv. 2021. PMID: 34581757. doi:10.1182/bloodadvances.2021004619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。